Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.

Bayle, A; Khettab, M; Lucibello, F; Chamseddine, A N; Goldschmidt, V; Perret, A; Ropert, S; Scotté, F; Loulergue, P; Mir, O

Bayle, A; Khettab, M; Lucibello, F; Chamseddine, A N; Goldschmidt, V; Perret, A; Ropert, S; Scotté, F; Loulergue, P; Mir, O.

Afiliação

Bayle A; Department of Drug Development/DITEP, Gustave Roussy Cancer Institute, Villejuif, France.
Khettab M; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Chevilly-Larue, France.
Lucibello F; INSERM U932, Paris Sciences et Lettres University, Curie Institute, Paris, France.
Chamseddine AN; Department of International Patients Cancer Care.
Goldschmidt V; Ambulatory Cancer Care.
Perret A; Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Ropert S; Department of Medical Oncology, Antony Private Hospital, Antony, France.
Scotté F; Department of Medical Oncology, Foch Hospital, Suresnes, France.
Loulergue P; Department of Infectious Diseases, Hôtel-Dieu Teaching Hospital, Paris, France.
Mir O; Ambulatory Cancer Care. Electronic address: olivier.mir@gustaveroussy.fr.

Ann Oncol ; 31(7): 959-961, 2020 07.

Article em En | MEDLINE | ID: mdl-32224150

Assuntos

Influenza Humana; Neoplasias; Antígeno B7-H1; Humanos; Neoplasias/tratamento farmacológico; Receptor de Morte Celular Programada 1; Vacinação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Influenza Humana / Neoplasias Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google